Our in vitro study showed that lenalidomide and pomalidomide, but not thalidomide, induced PD-L1 expression on IMiD-insensitive MM cell lines and plasma cells from relapsed/refractory MM patients through the BCMA–APRIL pathway. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.